Bayer Healthcare LLC

Bayer Pharma Aktiengesellschaft

Basf Agricultural Solutions Seed US LLC

Crispr Therapeutics Ag

Bayer Aktiengesellschaft

Boehringer Ingelheim International Gmbh

Bayer Intellectual Property Gmbh

Jan Tebbe

Wayne Coco

Nina Wobst

Michael Strerath

Zhuozhi Wang

Christian Votsmeier

Susanne Steinig

Peter Scholz

Ernst Weber

Simone Greven

Christoph Mahlert

Fabien Poree

Bernd Laber

Gudrun Lange

Manuel Dubald

Marc Linka

Joerg Birkenfeld

Junliang Pan

Nikolaus Pawlowski

Frank Wunder

Hans-Georg Lerchen

Nils Griebenow

Anne-Sophie Rebstock

Beatrix Stelte-Ludwig

Yolanda Cancho Grande

Uwe Gritzan

Oliver Kensch

Damian Brockschnieder

Anette Sommer

Ulrich Haupts

Ji-Yun Kim

Tobias Marquardt

Thomas Mondritzki

Frank Dittmer

Joanna Grudzinska-Goebel

Lars Linden

Ricarda Finnern

Axel Harrenga

Xiao-Yan Zhao

Ryo Takeuchi

Jörg Willuda

Sandra Geske

Heike Balven-Ross

Simone Brückner

Christina Thies

Andreas Scheidig

Andreas Wilmen

Ying Zhu

Kornelia Kirchner

Kerstin Baral

Klaus Pellengahr

Hanna Plittersdorf

Joanna Grudzinska

Simone Brueckner

Andre Cohnen

Moritz Schmidt

Ashish Gupta

Christian Pitzler

Michael Biag Gamalinda

Florian Richter

Ilka Mathar

Lucas Hudson Hofmeister

Christopher J Cheng

Wayne M Coco

Corinna Saalwächter

Anke Mayer-bartschmid

Stuart Walsh

Marcel Geertz

Claudia Noack

Caroline W Reiss

Hannah Jörissen

Gabriele Leder

Cindy Schulenburg

Sabine Jach

Anup Arumughan

Juergen Franz

Yong-Jiang Cao

Jörg Birkenfeld

Simone BRÜCKNER

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Brain natriuretic peptide engrafted antibodies

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Atrial natriuretic peptide engrafted antibodies

Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.

RNA-programmable endonuclease systems and uses thereof

The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Site specific homogeneous with KSP inhibitors

Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease fromor variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.

RNA-programmable endonuclease systems and their use in genome editing and other applications

In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.

HPPD variants and methods of use

Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.

Humanized monoclonal antibodies against activated protein c and uses thereof

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Humanized monoclonal antibodies against activated protein C and uses thereof

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF&#x3b1;); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

Antibodies to TNF&#x3b1;

Growing community of inventors

Cologne, Germany

Jan Tebbe